Biznesradar bez reklam? Sprawdź BR Plus
Biznesradar bez reklam? Sprawdź BR Plus
**Tenax Therapeutics Reports Q4 2025 Results**
The post Tenax Therapeutics Inc (TENX) Reports Q4 Earnings first appeared on Alphastreet.
Cullinan Therapeutics posts $0.73 per share loss in Q4 2025, matching year-ago results as the pre-revenue biotech maintains clinical development focus.
The post Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year first appeared on Alphastreet.
BETA Technologies reported a Q4 loss of $1.71/share vs expected $0.47 loss, but guided 2026 revenue to $130M-$135M as certification milestones advance.
The post BETA Technologies Reports Wider Q4 Loss of $1.71/Share vs $0.47 Estimate, Guides 2026 Revenue to $130M-$135M first appeared on Alphastreet.
Septerna reports Q4 loss of $0.24/share, wider than expected, as revenue climbs to $24.1M from minimal levels earlier in fiscal 2025.
The post Septerna (SEPN) Reports Narrower Q4 Loss of $0.24/Share as Revenue Climbs to $24.1M first appeared on Alphastreet.
Dyne Therapeutics narrows Q4 loss to $0.73/share vs $0.76 estimate; shares jump 19% as clinical-stage biotech shows sequential improvement.
The post Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate; Shares Surge 19% first appeared on Alphastreet.
Priority Technology Holdings posted Q4 adjusted EPS of $0.27, up 621% year-over-year, with revenue climbing 8.8% to $247.1 million.
The post Priority Technology (PRTH) reports Q4 Adjusted EPS of $0.11, Revenue Up 8.8% first appeared on Alphastreet.
**SuRo Capital Corp Reports Wider-Than-Expected Q4 Loss**
The post SuRo Capital Corp (SSSS) Reports Wider Loss Q4 Estimates by 10.0% first appeared on Alphastreet.
Opus Genetics posts $0.80 Q4 loss as revenue surges 230% year-over-year to $14.2M on collaboration activity.
The post Opus Genetics (IRD) Reports $0.80 Q4 Loss Despite 230% Revenue Surge to $14.2M first appeared on Alphastreet.
Prelude Therapeutics reports Q4 loss of $1.29/share, 616.7% wider than expected, despite revenue jumping to $12.1M from $6.5M sequentially.
The post Prelude Therapeutics (PRLD) Q4 Loss Widens 616.7% to $1.29/Share as Revenue Climbs to $12.1M first appeared on Alphastreet.
Yalla Group's Q4 adjusted EPS of $0.21 and revenue of $83.9M matched the prior quarter exactly, signaling a growth plateau.
The post Yalla Group (YALA) Q4 Earnings Flat at $0.21 EPS, $83.9M Revenue Signals Growth Stall first appeared on Alphastreet.
Yalla Group reports Q4 adjusted EPS of $0.21 on flat sequential revenue of $83.9M, maintaining profitability but showing zero growth.
The post Yalla Group (YALA) Reports Q4 EPS of $0.20 as Revenue Stalls at $83.9M first appeared on Alphastreet.
FuelCell Energy narrows Q1 loss to $0.52/share vs $0.68 estimate, but revenue of $30.5M misses $43.3M consensus by 29.5% on module timing.
The post FuelCell Energy (FCEL) Q1 Loss Narrows to $0.52/Share vs $0.68 Estimate, Revenue Misses by 29.5% first appeared on Alphastreet.
BETA Technologies reported Q4 loss of $1.71/share vs expected $0.47 loss; revenue $32.1M; guides 2026 revenue $130M-$135M, up 265% year-over-year.
The post BETA Technologies (BETA) Reports Wider Q4 Loss But Forecasts Triple-Digit Revenue Growth for 2026 first appeared on Alphastreet.
Yext reports Q4 adjusted EPS of $0.15, matching prior quarter, as revenue stalls at $112M year-over-year.
The post Yext (YEXT) Q4 Earnings: $0.15 EPS as Revenue Flatlines at $112M first appeared on Alphastreet.
FuelCell Energy narrows Q1 loss to $0.52/share vs $0.68 estimate, but revenue of $30.5M misses $43.3M consensus by 30% on timing delays.
The post FuelCell Energy (FCEL) Q1 Loss Narrows to $0.52/Share vs $0.68 Estimate; Revenue Misses by 30% first appeared on Alphastreet.
Legend Biotech (NASDAQ: LEGN) reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting continued...
The post Legend Biotech Q4 2025 Earnings Results first appeared on Alphastreet.
ABM Industries (NYSE: ABM) reported financial results for the first quarter of fiscal 2026, delivering solid revenue growth driven by...
The post ABM Industries Q1 FY26 Earnings Results first appeared on Alphastreet.
Revenue Performance Unusual Machines reported robust top-line expansion for the fourth quarter and full year ended December 31, 2025. Full-year...
The post Unusual Machines Q4 FY25 Earnings Results first appeared on Alphastreet.
Revenue Performance ACCO Brands Corporation reported full-year 2025 net sales of $1.525 billion, representing an 8.5 percent decline from the...
The post ACCO Brands Q4 FY25 Earnings Results first appeared on Alphastreet.
TL;DR: Washington is tightening the screws on tech M&A, and the message from regulators is clear: the era of Big...
The post U.S. Regulators Turn Up the Heat on Big Tech Acquisitions first appeared on Alphastreet.
Revenue Growth and Net Income Metrics Sharplink posted substantial top-line expansion for the full year ended December 31, 2025, recording...
The post Sharplink Q4 FY25 Earnings Results first appeared on Alphastreet.
Revenue Performance ARS Pharmaceuticals recorded total revenue of $28.1 million for the fourth quarter of 2025, driven largely by $20.3...
The post ARS Pharmaceuticals Q4 FY25 Earnings Results first appeared on Alphastreet.
Revenue Performance Kohl’s Corporation reported a decline in top-line results for both the fourth quarter and the full fiscal year...
The post Kohl’s Corporation Q4 FY25 Earnings Results first appeared on Alphastreet.
Repay posts $0.24 adjusted EPS on flat $77.7M revenue, with GAAP loss of $6.6M highlighting profitability adjustments ahead of tonight's call.
The post Repay (RPAY) Reports $0.24 Adjusted EPS on $77.7M Revenue, Posts $6.6M GAAP Loss first appeared on test.
CEO Carsten Brunn sold 23,766 shares at $6.82 per share, totaling $162,077, while retaining 323,530 shares.
The post RNAC CEO Carsten Brunn Sells 23,766 Shares at $6.82, Retains 323,530 Shares first appeared on test.
Biznesradar bez reklam? Sprawdź BR Plus
Biznesradar bez reklam? Sprawdź BR Plus
